Baxter (NYSE:BAX) today released new data from studies exploring expanded hemodialysis with its Theranova dialyzer, touting the device’s ability to clear large middle molecules at a higher rate than standard hemodialysis and equal or faster removal rates compared to high-volume hemodiafiltration.
Results from a number of studies and poster presentations on the Theranova dialyzer were presented at the 55th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this month, Baxter said.
The Deerfield, Ill.-based company’s Theranova dialyzer is designed to extend the range of molecules that it filters from the blood, which the company claims “more closely mimics the natural kidney.” The expanded hemodialysis therapy works on standard equipment and does not require the generation of replacement fluid, Baxter said.
Baxter touted that data from two studies presented at the meeting indicated that during treatment with the Theranova dialyzer, albumin levels remained stable during treatment.
In an independent study exploring the effects of its HDx therapy in comparison to high-flux HD in conventional settings, data indicated no loss of serum albumin or serum protein with use of the Theranova dialyzer in conventional HD compared to high-flux dialyzer hemodiafiltration. No relevant differences in adequacy, anemia or bone mineral metabolism parameters were noted, Baxter added.
A separate independent study, researchers found Baxter’s HDx to be superior to standard high-flux HD in removing middle and larger molecules, and found it non-inferior to hemodiafiltration in clearing small and larger middle molecules.
“HDx therapy enabled by Theranova was designed to filter a wider range of toxins from the blood than conventional HD filters, because we believe this is a critical step to transforming renal care and improving patient outcomes. We are committed to fully exploring and supporting robust scientific exchange about HDx therapy to understand its full potential for dialysis patients,” Baxter renal care biz GM Laura Angelini said in a press release.
Earlier this week, Baxter announced the launch of two updates for its Sharesource remote patient monitoring platform designed to monitor home peritoneal dialysis patients including the addition of a new modeling software tool and improvements to the clinical portal.
